PRLD

SEC source: 0001209191-21-048688 · doc4.xml · nonDerivative · entry 1

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

SEC source: 0001209191-21-047835 · doc4.xml · derivative · entry 1

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,650

Underlying: Common Stock · 115,650 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047841 · doc4.xml · derivative · entry 1

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047847 · doc4.xml · derivative · entry 1

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047845 · doc4.xml · derivative · entry 1

Vaddi Krishna · CIK 0001824633 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,800

Underlying: Common Stock · 285,800 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047831 · doc4.xml · derivative · entry 1

Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047842 · doc4.xml · derivative · entry 1

Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047839 · doc4.xml · derivative · entry 1

Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-047500 · doc4.xml · derivative · entry 1

Babler Martin · CIK 0001435618 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,400

Underlying: Common Stock · 36,400 shares

Expires 2031-07-18

F1 · derivative.exercise_date: The stock option vested as to 1/36 of the total shares monthly beginning on August 19, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-046013 · doc4.xml · derivative · entry 5

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,610

Underlying: Common Stock · 15,000 shares

Expires 2029-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-046013 · doc4.xml · nonDerivative · entry 4

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-046013 · doc4.xml · nonDerivative · entry 3

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-046013 · doc4.xml · nonDerivative · entry 2

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,555

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.74 to $27.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-046013 · doc4.xml · nonDerivative · entry 1

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001638599-21-000590 · doc4_7283.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 23,344

Underlying: Common Stock · 23,344 shares

Expires 2031-06-17

F1 · derivative.exercise_date: 23,344 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Prelude Therapeutics Incorporated (the "Issuer") were granted under the Issuer's 2016 Stock Incentive Plan, as Amended and Restated, to Julian C. Baker, a managing member of Baker Bros. Advisors LP (the "Adviser"), in his capacity as a director of the Issuer. The Stock Options have a strike price of $31.02 per share, and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general shareholders' meeting of the Issuer, subject to Julian C. Baker's continued service on the Board of Directors of the Issuer (the "Board") or an earlier change in control of the Issuer.

F1 · ownership.nature: 23,344 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Prelude Therapeutics Incorporated (the "Issuer") were granted under the Issuer's 2016 Stock Incentive Plan, as Amended and Restated, to Julian C. Baker, a managing member of Baker Bros. Advisors LP (the "Adviser"), in his capacity as a director of the Issuer. The Stock Options have a strike price of $31.02 per share, and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general shareholders' meeting of the Issuer, subject to Julian C. Baker's continued service on the Board of Directors of the Issuer (the "Board") or an earlier change in control of the Issuer.

F2 · ownership.nature: Julian C. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have any right to any of the Issuer's securities issued as part of her service on the Board and the Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-21-042466 · doc4.xml · derivative · entry 1

Bonita David P · CIK 0001572451 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,344

Underlying: Common Stock · 23,344 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · ownership.direct: These securities are held of record by David P. Bonita ("Bonita"), a member of OrbiMed Advisors LLC ("Advisors"). Pursuant to an agreement with Advisors and OrbiMed Capital GP VI LLC ("GP VI"), Bonita is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP VI, which will in turn ensure that such securities of economic benefits are provided to OrbiMed Private Investments VI, LP ("OPI VI").

F3 · ownership.direct: Each of GP VI and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Bonita, to serve on the Company's board of directors. This report shall not be deemed an admission that GP VI or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

F4 · ownership.direct: GP VI is the general partner of OPI VI and Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.

SEC source: 0001209191-21-042474 · doc4.xml · derivative · entry 1

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,344

Underlying: Common Stock · 23,344 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-042471 · doc4.xml · derivative · entry 1

Dier Mardi · CIK 0001574591 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,344

Underlying: Common Stock · 23,344 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-042476 · doc4.xml · derivative · entry 1

Sandor Victor · CIK 0001620368 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,344

Underlying: Common Stock · 23,344 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-21-039261 · doc4.xml · derivative · entry 5

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,610

Underlying: Common Stock · 15,000 shares

Expires 2029-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-039261 · doc4.xml · nonDerivative · entry 4

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.21 to $33.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-039261 · doc4.xml · nonDerivative · entry 3

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,700

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $32.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-039261 · doc4.xml · nonDerivative · entry 2

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,600

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.97 to $30.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-039261 · doc4.xml · nonDerivative · entry 1

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-036297 · doc4.xml · derivative · entry 6

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,662

Underlying: Common Stock · 8,333 shares

Expires 2029-08-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on July 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-036297 · doc4.xml · nonDerivative · entry 5

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-036297 · doc4.xml · nonDerivative · entry 4

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.91 to $35.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-036297 · doc4.xml · nonDerivative · entry 3

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,135

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.83 to $34.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-036297 · doc4.xml · nonDerivative · entry 2

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,223

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.83 to $33.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-036297 · doc4.xml · nonDerivative · entry 1

Piper Brian · CIK 0001665924 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-031847 · doc4.xml · derivative · entry 5

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,460

Underlying: Common Stock · 10,000 shares

Expires 2028-11-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 4

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,920

F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

SEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 3

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,120

F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $41.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

SEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 2

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,956

F2 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

SEC source: 0001209191-21-031847 · doc4.xml · nonDerivative · entry 1

Scherle Peggy · CIK 0001824632 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

SEC source: 0001209191-21-031248 · doc4.xml · derivative · entry 5

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,610

Underlying: Common Stock · 15,000 shares

Expires 2029-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-031248 · doc4.xml · nonDerivative · entry 4

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.70 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-031248 · doc4.xml · nonDerivative · entry 3

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,109

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.70 to $40.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-031248 · doc4.xml · nonDerivative · entry 2

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,585

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.70 to $39.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-031248 · doc4.xml · nonDerivative · entry 1

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-029352 · doc4.xml · derivative · entry 3

Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,323

Underlying: Common Stock · 3,295 shares

Expires 2030-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-029352 · doc4.xml · nonDerivative · entry 2

Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,750

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-029352 · doc4.xml · nonDerivative · entry 1

Pierce Christopher · CIK 0001824631 · EVP and Chief of Business Oper

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-029351 · doc4.xml · derivative · entry 3

Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,323

Underlying: Common Stock · 3,223 shares

Expires 2030-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-029351 · doc4.xml · nonDerivative · entry 2

Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $41.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-029351 · doc4.xml · nonDerivative · entry 1

Morosini Deborah · CIK 0001824625 · EVP, Chief of Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-029033 · doc4.xml · derivative · entry 5

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,610

Underlying: Common Stock · 25,000 shares

Expires 2029-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested as to 25% of the total shares monthly on May 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-029033 · doc4.xml · nonDerivative · entry 4

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.08 to $36.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-029033 · doc4.xml · nonDerivative · entry 3

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,711

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.08 to $36.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-21-029033 · doc4.xml · nonDerivative · entry 2

Mauro David J · CIK 0001621172 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,312

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $35.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.